Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers

European Journal of Cancer

Volumn 49, Issue 4, 2013, Pages 852-859

  Takahashi, Hidenori ^a   Okamoto, Masato ^b   Shimodaira, Shigetaka ^c   Tsujitani, Shun Ichi ^d   Nagaya, Masaki ^a   Ishidao, Takefumi ^e   Kishimoto, Junji ^f   Yonemitsu, Yoshikazu ^g  

^a Seren Clinic   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e Kirin Food Tech   (Japan)

^f KYUSHU UNIVERSITY HOSPITAL   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

Author keywords

Dendritic cell vaccine; Non small cell lung cancer; Overall survival; Wilms' tumour 1

Indexed keywords

DENDRITIC CELL VACCINE; HEMOGLOBIN; HLA A ANTIGEN; PICIBANIL; TUMOR PROTEIN; UNCLASSIFIED DRUG; WILMS TUMOR PROTEIN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FEVER; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 84873742288     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.005     Document Type: Article

References (31)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. P. Bonomi, K. Kim, and D. Fairclough Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial J Clin Oncol 18 2000 623 631
3. C.J. Langer, J. Manola, and P. Bernardo Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial J Natl Cancer Inst 94 2002 173 181
4. A.B. Sandler, J. Nemunaitis, and C. Denham Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmall-cell lung cancer J Clin Oncol 18 2000 122 130
5. J.H. Schiller, D. Harrington, and C.P. Belani Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
6. Y. Ohe, Y. Ohashi, and K. Kubota Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan Ann Oncol 18 2007 317 323
7. L.G. Paz-Ares, B. Biesma, and D. Heigener Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer J Clin Oncol 30 2012 3084 3092
8. P. van der Bruggen, C. Traversari, and P. Chomez A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 1991 1643 1647
9. H. Sugiyama Editorial review Curr Opin Immunol 20 2008 206 210
10. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunotherapy: moving beyond current vaccines Nat Med 10 2004 909 915
11. D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects Nat Rev Immunol 4 2004 941 992
12. R.M. Steinman, and J. Banchereau Taking dendritic cells into medicine Nature 449 2007 419 426
13. P.J. Tacken, I.J. de Vries, R. Torensma, and C.G. Figdor Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting Nat Rev Immunol 7 2007 790 802
14. K. Palucka, H. Ueno, J. Fay, and J. Banchereau Dendritic cells and immunity against cancer J Intern Med 269 2011 64 73
15. C.G. Figdor, I.J. de Vries, W.J. Lesterhuis, and C.J. Melief Dendritic cell immunotherapy: mapping the way Nat Med 10 2004 475 480
16. F.J. Hsu, C. Benike, and F. Fagnoni Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med 2 1996 52 58
17. M.W. Perroud Jr, H.N. Honma, and A.S. Barbeiro Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study J Exp Clin Cancer Res 30 2011 65
18. M.A. Morse, T.M. Clay, and A.C. Hobeika Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecule Clin Cancer Res 11 2005 3017 3024
19. G.C. Chang, H.C. Lan, and S.H. Juang A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma Cancer 103 2005 763 771
20. E.A. Hirschowitz, T. Foody, R. Kryscio, L. Dickson, J. Sturgill, and J. Yannelli Autologous dendritic cell vaccines for non-small-cell lung cancer J Clin Oncol 22 2004 2808 2815
21. M. Okamoto, S. Furuichi, and Y. Nishioka Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation Cancer Res 64 2004 5461 5470
22. M. Okamoto, T. Oshikawa, and T. Tano Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432 J Natl Cancer Inst 95 2003 316 326
23. H. Sugiyama WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy Jpn J Clin Oncol 40 2010 377 387
24. M.A. Cheever, J.P. Allison, and A.S. Ferris The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 15 2009 5323 5337
25. Y. Oji, S. Miyoshi, and H. Maeda Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers Int J Cancer 100 2002 297 303
26. S. Nakatsuka, Y. Oji, and T. Horiuchi Immunohistochemical detection of WT1 protein in a variety of cancer cells Mod Pathol 19 2006 804 814
27. Y. Kimura, J. Tsukada, and T. Tomoda Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in the patients with advanced pancreatic carcinoma Pancreas 41 2012 195 205
28. F.O. Ademuyiwa, C.S. Johnson, and A.S. White Prognostic factors in stage III non-small-cell lung cancer Clin Lung Cancer 8 2007 478 482
29. J.P. Sculier, J.J. Lafitte, and J. Lecomte European Lung Cancer Working Party. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer Ann Oncol 18 2007 1037 1042
30. V.D. Mottironi, S.M. Banks, B. Pollara, and U.H. Rudofsky HLA and survival in lung cancer Clin Immunol Immunopathol 45 1987 55 62
31. A. Lin, X. Zhang, Y.Y. Ruan, Q. Wang, W.J. Zhou, and W.H. Yan HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer Lung Cancer 74 2011 504 509